|
25 Dec 2025 |
SIS
|
Consensus Share Price Target
|
332.50 |
421.25 |
- |
26.69 |
buy
|
|
|
|
|
06 Nov 2025
|
SIS
|
Motilal Oswal
|
332.50
|
410.00
|
339.40
(-2.03%)
|
23.31 |
Buy
|
|
|
SIS (SECIS)’s 2QFY26 revenue was up 15% YoY/5.9% QoQ at INR37.6b vs. our estimate of INR35.6b. Revenue growth was aided by ~5.7% growth in India security, whereas International Security/Facilities management posted a growth of 1.9%(CC)/5.9% QoQ.
|
|
31 Jul 2025
|
SIS
|
Motilal Oswal
|
332.50
|
450.00
|
386.40
(-13.95%)
|
35.34 |
Buy
|
|
|
SIS (SECIS)’s 1QFY26 revenue was up 13.4% YoY/3.5% QoQ at INR35.4b vs. our estimate of INR34.5b. Revenue growth was aided by 18.9% YoY CC growth in Facility Management, whereas India Security/International Security posted 9.2%/12.1% growth YoY.
|
|
05 May 2025
|
SIS
|
Keynote Capitals Ltd
|
332.50
|
361.00
|
325.35
(2.20%)
|
Target met |
Buy
|
|
|
Quarterly Update Q4FY25
|
|
01 May 2025
|
SIS
|
Motilal Oswal
|
332.50
|
400.00
|
337.50
(-1.48%)
|
Target met |
Buy
|
|
|
SIS (SECIS)’s 4QFY25 revenue was up 9.3% YoY/1.9% QoQ at INR34.27b, largely in line with our estimate of INR34.6b. Revenue growth was aided by 12.9% YoY growth in Facility management, whereas India Security/International security posted 9.6%/7.7% growth YoY.
|
|
30 Jan 2025
|
SIS
|
Keynote Capitals Ltd
|
332.50
|
414.00
|
330.80
(0.51%)
|
24.51 |
Buy
|
|
|
Quarterly Update Q3FY25
|
|
31 Oct 2024
|
SIS
|
Keynote Capitals Ltd
|
332.50
|
483.00
|
402.00
(-17.29%)
|
|
Buy
|
|
|
Quarterly Update Q2FY25
|
|
30 Oct 2024
|
SIS
|
Axis Direct
|
332.50
|
540.00
|
400.85
(-17.05%)
|
|
Buy
|
|
|
Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock
|
|
29 Oct 2024
|
SIS
|
Motilal Oswal
|
332.50
|
480.00
|
386.05
(-13.87%)
|
|
Buy
|
|
|
SIS (SECIS)’s 2QFY25 revenue was up 6.3% YoY/4.4% QoQ at INR32.68b, largely in line with our estimate of INR34.51b.
|
|
29 Jul 2024
|
SIS
|
Keynote Capitals Ltd
|
332.50
|
585.00
|
421.25
(-21.07%)
|
|
Buy
|
|
|
Quarterly Update Q1FY25
|
|
26 Jul 2024
|
SIS
|
Axis Direct
|
332.50
|
540.00
|
419.75
(-20.79%)
|
|
Buy
|
|
|
We maintain our BUY recommendation on the stock.
|
|
06 May 2024
|
SIS
|
Keynote Capitals Ltd
|
332.50
|
441.00
|
440.50
(-24.52%)
|
Target met |
Buy
|
|
|
Quarterly Update Q4FY24
|
|
03 May 2024
|
SIS
|
Axis Direct
|
332.50
|
540.00
|
455.15
(-26.95%)
|
|
Buy
|
|
|
Recommendation: Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
01 Feb 2024
|
SIS
|
Keynote Capitals Ltd
|
332.50
|
741.00
|
488.50
(-31.93%)
|
|
Buy
|
|
|
Quarterly Update Q3FY24
|
|
01 Feb 2024
|
SIS
|
Axis Direct
|
332.50
|
540.00
|
488.50
(-31.93%)
|
|
Buy
|
|
|
Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
01 Nov 2023
|
SIS
|
Keynote Capitals Ltd
|
332.50
|
794.00
|
429.40
(-22.57%)
|
|
Buy
|
|
|
Quarterly Update Q2FY24
|
|
01 Nov 2023
|
SIS
|
Axis Direct
|
332.50
|
475.00
|
429.40
(-22.57%)
|
Target met |
Buy
|
|
|
Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
21 Sep 2023
|
SIS
|
Keynote Capitals Ltd
|
332.50
|
837.00
|
426.10
(-21.97%)
|
|
Buy
|
|
|
Initiating Coverage Report
|
|
28 Jul 2023
|
SIS
|
Axis Direct
|
332.50
|
475.00
|
434.65
(-23.50%)
|
Target met |
Buy
|
|
|
Recommendation: Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
05 May 2023
|
SIS
|
Axis Direct
|
332.50
|
425.00
|
383.35
(-13.26%)
|
Target met |
Buy
|
|
|
Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
06 Feb 2023
|
SIS
|
Axis Direct
|
332.50
|
425.00
|
345.95
(-3.89%)
|
Target met |
Buy
|
|
|
Recommendation: Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|